Rapid identification of Candida species facilitates pathogen-directed therapy with either fluconazole or an echinocandin.
Method
We applied Sepsityper matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF-MS) technology on positive blood culture broths for rapid species identification.
Results
Of the 74 patients with candidaemia, 25 had the species identified on the day of the positive blood culture directly from the broth (rapid identification group) while the remaining 49 had the species identified from culture (conventional identification group). Three (13.6%) out of 22 treated patients in the rapid identification group received echinocandin compared to 20/45 (44.4%) in the conventional identification group. The appropriateness of therapy was 90.9% in the rapid identification group and 62.2% in the conventional identification group (p = 0.01). Cost savings were more than £10,000 in the first three days of treatment.
Conclusion
Sepsityper-MALDI-TOF-MS is a useful tool in supporting antifungal stewardship programmes.
RajendranR, SherryL, DeshpandeA. A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. Front Microbiol2016; 7:915.
2.
OddsFC, HansonMF, DavidsonAD. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol2007; 56: 1066–75.
3.
SchelenzS, HagenF, RhodesJL. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control2016; 5:35.
4.
FalconeM, TiseoG, TasciniC. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. Eur J Intern Med2017; 41: 33–8.
5.
KlotzU, SchmidtD, WillingerB. Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria. Mycoses2016; 59: 312–8.
6.
PappasPG, KauffmanCA. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis2016; 62: e1–50.
7.
MetwallyL, HoggG, CoylePV. Rapid differentiation between fluconazole-sensitive and -resistant species of Candida directly from positive blood-culture bottles by real-time PCR. J Med Microbiol2007; 56: 964–70.
8.
CornelyOA, BassettiM, CalandraT. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect2012; 18 (Suppl 7):19–37.
9.
SmischneyNJ, DemirciO, RicterBD. Vasopressor use as a surrogate for post-intubation hemodynamic instability is associated with in-hospital and 90-day mortality: a retrospective cohort study. BMC Res Notes2015; 8:445.
10.
YangS, WuX, YuW. Early enteral nutrition in critically ill patients with hemodynamic instability: an evidence-based review and practical advice. Nutr Clin Pract2014; 29: 90–6.
11.
BalAM, ShanklandGS, ScottG. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract2014; 68: 20–7.
12.
JeddiF, Yapo-KouadioGC, NormandAC. Performance assessment of two lysis methods for direct identification of yeasts from clinical blood cultures using MALDI-TOF mass spectrometry. Med Mycol2017; 55: 185–92.
13.
KullbergBJ, VerweijPE, AkovaM. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect2011; 17 (Suppl 5):1–12.
14.
GareyKW, RegeM, PaiMP. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis2006; 43: 25–31.
15.
DeshpandeA, GaurS, BalAM. Candidaemia in the non-neutropenic patient: a critique of the guidelines. Int J Antimicrob Agents2013; 42: 294–300.
16.
PfallerMA, CastanheiraM. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol2016; 54: 1–22.
17.
BassettiM, PeghinM, TimsitJF. The current treatment landscape: candidiasis. J Antimicrob Chemother2016; 71 (suppl 2): ii13–ii22.
18.
NathwaniD, SneddonJ, MalcolmW. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents2011; 38: 16–26.
19.
AlexanderBD, AshleyED, RellerLB. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis2006; 54: 277–82.
20.
McMullanR, MetwallyL, TroughtonJA. The impact of a PCR assay for candidemia on antifungal drug prescribing in critical care: an interrupted time series pilot study. J Infect2010; 61: 81–5.
21.
GortonRL, RamnarainP, BarkerK. Comparative analysis of Gram's stain, PNA-FISH and Sepsityper with MALDI-TOF MS for the identification of yeast direct from positive blood cultures. Mycoses2014; 57: 592–601.
22.
IdelevichEA, GrunewaldCM, WullenweberJ. Rapid identification and susceptibility testing of Candida spp. from positive blood cultures by combination of direct MALDI-TOF mass spectrometry and direct inoculation of Vitek 2. PLoS One2014; 9: e114834.
23.
SpanuT, PosteraroB, FioriB. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol2012; 50: 176–9.
24.
ReboliAC, RotsteinC, PappasPG. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med2007; 356: 2472–82.
25.
ImtiazT, LeeKK, MunroCA. Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin. J Med Microbiol2012; 61: 1330–4.
